Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

85.82 +0.77 (+0.91%)
Official Closing Price Updated: 4:15 PM EDT, Oct 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
Why Gilead Sciences Investors Shouldn't Give Up on Remdesivir Just Yet
A new study shows it is highly effective in preventing deaths if taken early. 
Via The Motley Fool
Topics Death
Exposures COVID-19 Death
NanoViricides Leaps Forward in its Quest to Defeat COVID-19
Photo by Louis Reed on Unsplash Since the coronavirus pandemic started, scientists have worked to develop a vaccine to inoculate the population and stop the spread of COVID-19.... 
Via Benzinga
Exposures COVID-19
Tesla and Merck Give Investors Some Hope
Friday’s rally appears to have lost its momentum over the weekend because stock futures are trading lower before Monday’s open. China’s troubled real estate... 
Via Benzinga
Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn's Disease
Galapagos NV (NASDAQ: GLPG) has randomized the last patient into the DIVERSITY Phase 3 study of filgotinib in the induction and maintenance of remission in... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
Gilead's Kite Files US Application To Expand Use Of Yescarta In Second-Line Setting
Kite Pharma, a Gilead Science Inc Company (NASDAQ: GILD), has submitted a supplemental marketing application to the FDA for Yescarta (axicabtagene ciloleucel... 
Via Benzinga
Exposures Product Safety
3 Top Dividend Stocks Yielding More Than 4%
Make the most of your money with these generous income stocks. 
Via The Motley Fool
Merck's COVID-19 Antiviral Pill Effective Against Variants, Lab Studies Show
Merck & Co Inc (NYSE: MRK) presented a study at a medical conference early Wednesday for its experimental COVID-19 antiviral candidate. What Happened: Laboratory... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
GSK, Pfizer Backed Long-Acting HIV Med Under FDA Priority Review As Preventative Option
The FDA has accepted and granted Priority Review to ViiV Healthcare's marketing application seeking approval for injectable cabotegravir long-acting for... 
Via Benzinga
Exposures Product Safety
Gilead Scores Fifth Approval For Trodelvy In Triple-Negative Breast Cancer, This Time In Canada
Health Canada has approved Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan-hziy) for previously treated breast cancer patients. The approval... 
Via Benzinga
Pfizer Begins Late-Stage Study To Test Effectiveness Of Oral Drug Against COVID-19 In Those Exposed To The Virus
Pfizer Inc (NYSE: PFE) says it has begun late-stage testing for an oral drug that can be taken by persons who are exposed to the virus that causes COVID-19. What Happened: The New... 
Via Benzinga
Exposures COVID-19
Acceleron Stock Heats Up On $11 Billion Takeover Rumor; So, Who's The Buyer?
A biotech working in lung and blood diseases, as well as cancer, could be acquired. 
Via Investor's Business Daily
Acceleron In Advanced $11B Buyout Talks: Bloomberg
Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ: XLRN) were capped with a Bloomberg report asserting that the Company is... 
Via Benzinga
7 Members Of Congress Failed To Disclose Stock Transactions: Who Was Named, And What's Next?
The call for members of Congress to be banned from buying and selling stocks continues to heat up with a new report that seven members of the House of Representatives failed to... 
Via Benzinga
3 Relatively Safe Pharma Stocks You Can Buy Right Now
These stocks should be less volatile than many of the alternatives. 
Via The Motley Fool
EXCLUSIVE: NanoViricides' Remdesivir-Encapsulated COVID-19 Therapy Shows Encouraging Preclinical Safety Profile
NanoViricides Inc (NYSE: NNVC) has reported significant advantages gained by remdesivir encapsulation within its lead COVID-19 candidate, thus showing a potential pan-... 
Via Benzinga
Exposures COVID-19
Barron's Latest Picks And Pans: Apple, Bitcoin, a Goldman Sachs ETF, Nike And More
This weekend's Barron's cover story examines the t... 
Via Benzinga
Baidu, Gilead Sciences And Nvidia Stocks Provide Plays For Both Bulls And Bears: Here's How
Baidu. Inc (NASDAQ:BIDU), Gilead Sciences, Inc 
Via Benzinga
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (... 
Via Benzinga
Look For The Q4 Biotech Bounce In Mid-Small Caps
Large-cap biopharma stocks are off their highs because of prospects that drug prices may be directly negotiated through Medicare but several Democrats are not in agreement as to how this could be best... 
Via Talk Markets
Gilead Churns Out Additional Trodelvy Data
Gilead Sciences Inc (NASDAQ: GILD) announced new data from the Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory metastatic... 
Via Benzinga
This Cancer Screening Company Has A Better 5-Year Return Than Pfizer, Johnson & Johnson And Gilead
Small-cap stocks have a history of outperforming large-cap names as they have the potential for rapid growth and have event-driven moves for share prices. A company focused... 
Via Benzinga
COVID 19 Stocks -- Vaccines, Diagnostics, or Treatments?
Which subset of the COVID-19 healthcare market will outperform over the next year? 
Via The Motley Fool
Exposures COVID-19
A Look Into Gilead Sciences Debt
Shares of Gilead Sciences (NASDAQ:GILD) rose by 7.09% in the past three months. Before we understand the importance of debt, let us look at how much debt Gilead Sciences... 
Via Benzinga
Galapagos' Long-Serving CEO Onno Van De Stolpe To Exit After R&D Setbacks
After 22 years at the helm of Galapagos NV (NASDAQ: GLPG), chief executive Onno van de Stolpe has decided it is time to retire and hand the reins to new... 
Via Benzinga
Could Moderna Take Down Gilead Sciences?
It's too early for a "yes" answer. But it's too premature for a "no" response as well. 
Via The Motley Fool
Gilead Wins Reversal of $1.2B Patent Loss to Bristol-Myers: Bloomberg
Gilead Sciences Inc (NASDAQ: GILD) persuaded a U.S. appeals court to reverse a $1.2 billion judgment Bristol-Myers Squibb & Co (NYSE: BMY) had won over immuno-... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Siemens' Fatty Liver Disease Blood Test Wins FDA De Novo Clearance
The FDA has granted clearance to a blood test from Siemens Healthineers (OTC: SMMNY) to provide an easier and potentially more accurate diagnostic alternative than an invasive... 
Via Benzinga
Exposures Product Safety
Now That The FDA Approved Pfizer-BioNTech, Is This It For Vaccine Stocks?
If there's one thing to take away from any conversation about biotech stocks, it's that any company with their hat in the ring is likely making a version of something they hope to be better than the... 
Via Talk Markets
Exposures Product Safety
< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.